From Canada.com:
The side-effects of a popular asthma medication that has been sold in Canada for 12 years has been linked to suicide attempts and thoughts of suicide, as well as feelings of depression and hostility.
The July 2009 issue of the Canadian Adverse Reaction Newsletter from Health Canada cites montelukast sodium — which has been marketed in Canada since 1997 as Singulair — as having several connections to the alarming reactions.
Between its introduction to the Canadian market and Jan. 31, 2009, Singulair has been linked to two suicide attempts in Canada and 11 cases where users had thoughts of suicide or self-harm. In 29 other cases, 14 of which were labelled as "serious adverse reactions," those affected suffered from depression, hostility or other psychosis. No deaths have been linked to the drug's side-effects. ...more
Showing posts with label Singulair. Show all posts
Showing posts with label Singulair. Show all posts
Sunday, July 12, 2009
Sunday, March 30, 2008
FDA, Health Canada probing possible suicide link with allergy drug Singulair
From the Canadian Press:
U.S. and Canadian drug regulators are investigating the popular allergy medication Singulair in response to reports of mood changes, suicidal behaviour and suicide in patients.
The U.S. Food and Drug Administration said Thursday it is reviewing a handful of such patient reports and has asked Singulair's maker, Merck & Co., to dig deeper into its data for more evidence of possible links to suicide.
Meanwhile, "patients should not stop taking Singulair before talking to their doctor," the FDA said in a statement, adding that doctors should monitor patients for suicidal behaviour and mood changes.
Health Canada is also investigating a possible link between Singulair and suicidal behaviour, said spokesman Paul Duchesne, noting that consumers should see their doctors if they have concerns about taking the prescription drug.
He was unaware of any reports of suicide among Canadians taking the medication.
The FDA said it has not established a "causal relationship" between Merck's drug and suicidal behaviour. The review was prompted by three to four suicide reports it has received since last October, an agency spokeswoman said. ...more
U.S. and Canadian drug regulators are investigating the popular allergy medication Singulair in response to reports of mood changes, suicidal behaviour and suicide in patients.
The U.S. Food and Drug Administration said Thursday it is reviewing a handful of such patient reports and has asked Singulair's maker, Merck & Co., to dig deeper into its data for more evidence of possible links to suicide.
Meanwhile, "patients should not stop taking Singulair before talking to their doctor," the FDA said in a statement, adding that doctors should monitor patients for suicidal behaviour and mood changes.
Health Canada is also investigating a possible link between Singulair and suicidal behaviour, said spokesman Paul Duchesne, noting that consumers should see their doctors if they have concerns about taking the prescription drug.
He was unaware of any reports of suicide among Canadians taking the medication.
The FDA said it has not established a "causal relationship" between Merck's drug and suicidal behaviour. The review was prompted by three to four suicide reports it has received since last October, an agency spokeswoman said. ...more
Subscribe to:
Posts (Atom)